Insiders Are Selling These 5 Stocks in 2024

Page 1 of 5

This article presents an overview of Insiders Are Selling These 5 Stocks in 2024. For a detailed overview of such stocks, read our article, Insiders are Selling These 10 Stocks in 2024.

5. Medpace Holdings Inc (NASDAQ:MEDP)

Number of Hedge Fund Investors: 38

Ohio-based clinical research company Medpace Holdings Inc (NASDAQ:MEDP) ranks fifth in our list of the stocks insiders are selling in 2024.  Medpace Holdings Inc’s (NASDAQ:MEDP) CEO August J. Troendle on March 6 sold 200,000 shares of Medpace Holdings Inc (NASDAQ:MEDP) at $ 411.61 per share. On March 6 the stock closed trading at around $410.16. Since then through March 15 the stock has lost about 3.26% in value.

As of the end of the fourth quarter of 2023, 38 hedge funds out of the 933 funds tracked by Insider Monkey had stakes in Medpace Holdings Inc (NASDAQ:MEDP). The most significant stake in Medpace Holdings Inc (NASDAQ:MEDP) is owned by D. E. Shaw which had a $71 million stake in Medpace Holdings Inc (NASDAQ:MEDP).

Polen U.S. Small Company Growth Strategy stated the following regarding Medpace Holdings, Inc. (NASDAQ:MEDP) in its fourth quarter 2023 investor letter:

“Medpace Holdings, Inc. (NASDAQ:MEDP) is a mid-sized contract research organization (CRO) that services smaller biotech companies with venture/PE backing. Specifically, Medpace handles these companies’ clinical trial-related R&D, and their business model is built upon being a full-service only solution. Given our quality orientation, it is particularly challenging to buy pharma and biotech companies due to their earnings losses and FDA risk. The company’s impressive track record of robust financial performance—emphasizing stability, profitability, and well-above-average growth—offers us broad-based exposure to this industry. Medpace’s business model is designed to minimize the binary risks associated with single-company FDA concerns or unprofitability, making it an optimal choice for us as we seek exposure to the groundbreaking innovation that comes with the biotech industry.”

Page 1 of 5